Navigation Links
Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
Date:6/22/2013

CHICAGO, June 22, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from an additional analysis of Phase II clinical data for LY2605541, an investigational novel basal insulin analog. The analysis provides more in-depth information about the reductions in required prandial (mealtime) insulin in LY2605541-treated patients compared to those treated with insulin glargine.[1] These findings are being presented at the 73rd American Diabetes Association Scientific Sessions® in Chicago, June 21–25, 2013.

Initial clinical data from a Phase II study showed that LY2605541-treated patients with type 1 diabetes had greater improvements in glycemic control along with reduced mealtime insulin doses compared to insulin glargine-treated patients.[2] Results from this additional analysis showed that among those who completed the Phase II study, which included eight weeks of treatment with LY2605541 and eight weeks of insulin glargine, LY2605541 led to significantly lower average blood glucose levels (143.1 mg/dL vs. 151.7 mg/dL) with statistically significantly less mealtime insulin per day compared to insulin glargine. The reduced mealtime insulin use was found per day and across all major meals, including:

  • breakfast (-0.9 +/- 0.4 International Units (IU) [13.7 percent reduction]),
  • lunch (-1.4 +/- 0.4 IU [18.6 percent reduction]),
  • dinner (-2.0 +/- 0.4 IU [22.4 percent reduction]), and 
  • total daily dose (-4.3 +/- 1.5 IU) [20.7 percent reduction in units]).[1]

LY2605541-treated patients had a statistically higher overall hypoglycemia rate (blood glucose less than or equal to 70 mg/dL) compared to insulin glargine (9.2 vs. 8.1 events/30 days) but a statistically lower rate
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
5. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
8. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
9. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
10. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
11. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research ... "Global and Chinese Medical X-ray Film Industry Report ... http://photos.prnewswire.com/prnh/20130307/600769 Global And Chinese ... and in-depth study on the current state of the ... the Chinese situation. The report provides a basic ...
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2
... presented this week at the International Federation of Clinical ... lower diagnostic threshold for troponin improves clinical outcomes and ...  Troponin is a protein found inside of heart cells ... or reduced blood supply.   Cardiac troponin ...
... 18, 2011 The core technology of ViewRay™, Inc., ... radiotherapy technologies, has been issued landmark patents in the ... device company, holds the exclusive worldwide license for the ... technology was invented by company founder James F. Dempsey, ...
Cached Medicine Technology:Study Shows Improved Patient Management and Outcome Using Abbott's Sensitive Troponin Assay 2Study Shows Improved Patient Management and Outcome Using Abbott's Sensitive Troponin Assay 3Study Shows Improved Patient Management and Outcome Using Abbott's Sensitive Troponin Assay 4Landmark Patents Issued for ViewRay Technology 2
(Date:7/13/2014)... (PRWEB) July 14, 2014 Worldwide ladies ... selection. Angeldress.co.uk has taken a different approach and ... fresh items are offered in more colour choices that ... a famous brand of women’s special occasion apparels. The ... Its dress specialists are working hard to create the ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Ticket Down ... Real Madrid Tickets . For the fifth straight year ... Cup will be held at American stadiums this summer. The ... on American soil. The eight teams are split into two ... stage, the top two teams will compete to become champion. ...
(Date:7/13/2014)... inexpensive, portable, microchip-based test for diagnosing type-1 diabetes ... better understand the disease, according to the device,s ... , Described in a paper to be published ... the test employs nanotechnology to detect type-1 diabetes ... the two main forms of diabetes mellitus, which ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 The North American ... million in 2013 to $5,450 million by 2018, at a ... systems market is expanding at a rapid pace in North ... ever tightening laws on water & wastewater storage and collection, ... infrastructure. The market is expanding at a healthy rate in ...
(Date:7/13/2014)... 13, 2014 Fuel additives are chemicals, ... diesel, jet fuel, kerosene, and so on, in order ... for reducing the corrosion effects caused by fuels and ... to any fuel, provide economies of scale in the ... the overall cost of the fuel products. , The ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Announces Summer Sale For Pink And Red Bridesmaid Dresses; The Current Discount Is Up To 80% Off 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4
... more respectful, SAN DIEGO, March 19 Over one-third ... to three years, find a non-nursing,job, work part-time, or work ... AMN Healthcare, the largest health care staffing firm in,the country, ... baby,boomer nurses may be facing career burn-out. About 46 percent ...
... fast and precise ... ALTO, Calif., March 19 Varian Medical,Systems (NYSE: ... centers in North,America and Europe to further the development ... fast and precise,cancer treatments. RapidArc makes it possible to ...
... Names New President and CEO, MIAMI, March 19 ... (NPF) announced today that Joyce A.,Oberdorf has been named ... was most recently Vice President, Policy, Planning,and Communications at ... "Ms. Oberdorf is an outstanding choice to help NPF ...
... Johnson & Johnson Vision ... Contact Lenses, JACKSONVILLE, Fla., March 19 Johnson ... the ACUVUE(R) The Difference is,Real(TM) Trip to Beijing Sweepstakes, ... performance. The sweepstakes runs March 18,through April 11, 2008, ...
... China, March 19 /Xinhua-PRNewswire-FirstCall/ -- China,Nepstar Chain Drugstore Ltd. ... largest drugstore chain in China based on the number ... the,quarter and fiscal year ended December 31, 2007., ... December 31, 2007: -- Revenues increased 9.5% to ...
... Mustang at the New York, International Auto Show to raise money for breast ... ... Komen Race for the Cure - to $500 for ... more than $95 million in, cash and in-kind contributions for breast cancer education and ...
Cached Medicine News:Health News:Survey: 35% of Baby Boomer Nurses Plan a Career Change in the Next One to Three Years 2Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 2Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 3Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 4Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 5Health News:National Parkinson Foundation Announces Its New President and CEO 2Health News:National Parkinson Foundation Announces Its New President and CEO 3Health News:Experience a Close-Up View of the Beijing 2008 Olympic Games 2Health News:Experience a Close-Up View of the Beijing 2008 Olympic Games 3Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 2Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 3Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 4Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 5Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 6Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 7Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 8Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 9Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 10Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 11Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 12Health News:Ford Launches 'Warriors in Pink' Mustang for '09, Doubles Contributions To Race For The Cure 2
Zero clearance, front breathing, undercounter refrigeration system....
Designed to meet the requirements of reagent grade water for routine analysis....
... Basic Laboratory Needs, Synergy systems produce ultrapure water ... 1 to 1.2 L/min to meet the basic ... incorporates a dual-wavelength UV lamp (185 nm and ... of organic contaminants (< 5 ppb TOC when ...
... Compact System Produces Type I Water Directly from ... designed for scientists who need 5 to 15 ... not have easy access to acceptable quality pretreated ... 0.6 L/min of ultrapure (Type I) water on ...
Medicine Products: